HLA-A*26 Positive serves as an inclusion eligibility criterion in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial that contains HLA-A*26 Positive as an inclusion criterion, 1 is phase 2 (0 open).
Trials with HLA-A*26 Positive in the inclusion eligibility criteria most commonly target breast carcinoma .
Gm-csf, nelipepimut-s, and trastuzumab are the most frequent therapies in trials with HLA-A*26 Positive as an inclusion criteria .
Significance of HLA-A*26 Positive in Diseases
Breast Carcinoma +
HLA-A*26 Positive is altered in 0.06% of breast carcinoma patients .
HLA-A*26 Positive is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains HLA-A*26 Positive and breast carcinoma as inclusion criteria, 1 is phase 2 (0 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.